9-INS-RG-TR- SUPPLEMENTRY MTERILS B IRF mrn expression 1 Control Fatty liver NSH HCV αsm IRF 1 ERG IRF < -33 33- Steatosis (%) < Figure S1. IRF mrn expression is not expressed modulated by steatosis grade in human NFLD and HVC and is not expressed in hepatic stellate cells of sinusoidal endothelial cells.. Interferon regulatory factor (IRF) mrn expression in liver biopsies from control patients with normal liver (control; n=), patients with fatty liver (n=1), non-alcoholic steatohepatitis (NSH; n=) and with viral hepatitis C (HCV; n=11) stratified by their state of steatosis. B. Representative co-immunostaining images of IRF (pink stain) with erythroblast transformation-specific-related gene (ERG; brown stain) or αsmooth muscle actin (αsm; brown stain) in liver sections from selected patients, scale bar=1µm. Differences between patient groups tested by one-way NOV. 1
9-INS-RG-TR- B. IRF mrn expression HFDwks. 1. 1... RP HE HFD1wks Total liver 1 Weeks on HFD F/+ cells IRF mrn expression IRF F/ 3 1 1 Weeks on HFD Figure S. IRF expression is not modulated under high-fat feeding in mice. Representative images of histological analysis of liver sections from mice maintained on a high-fat diet (HFD) for 1 and weeks. Liver sections stained with hematoxylin and eosin (HE) red picrosirius (RP) to visualize collagen fibres. Immunohistochemical analysis of F/ and interferon regulatory factor (IRF). B. IRF mrn expression in total liver lysate and liver F/+ cells. Differences between diets/treatments determined by one-way NOV. ll values reported as mean ± SEM.
IRF mrn expression.. 1. 1.. Hepatocytes CTRL MCD BDL CCl. CTRL MCD BDL CCl B *** IRF mrn expression 3 1 *** Total liver Hepatocytes F/ + cells F/ - cells Total liver Hepatocytes F/ + cells F/ - cells Total liver Hepatocytes F/ + cells F/ - cells Total liver Hepatocytes F/ + cells F/ - cells CTRL MCD BDL CCl Figure S3. IRF mrn expression is not modulated in hepatocytes and is restricted to F/ + cells.. Interferon regulatory factor (IRF) mrn expression in hepatocytes from mice upon normal chow (CTRL), methionine-and-choline deficient (MCD) feeding, bile duct ligation (BDL) or carbon tetrachloride (CCl ) treatment. B. IRF mrn expression from total liver lysate, isolated hepatocytes and immunoselected F/ + and F/ - cells of mice upon NC, MCD feeding, BDL or CCl. n= per group, differences between groups determined by two-way NOV. ll values reported as mean ± SEM. *p<, ** p<,1 *** p<,1. 3
MWT+CCl hrs F/ + LMNCs MKO+CCl hrs IRF kda ctin kda Figure S. Myeloid-specific deletion of IRF in liver F/ + cells.. Immunoblot of interferon regulatory factor (IRF) protein in immunoselected liver F/ + cells from wildtype (MWT) mice and mice with a myeloid-specific deletion of IRF (MKO) upon carbon tetrachloride (CCl ) treatment. n=3 per group, differences between groups determined by two-way NOV. ll values reported as mean ± SEM. *p<, ** p<,1 *** p<,1.
MWT CCl wks MKO Ccl Irf -1 +1 B CCL mrn expression 1 1 F/ + cells ** CCL mrn expression 1 1 F/ + cells *** MWT MKO MWT MKO MWT MKO MWT MKO Sham CCl wks Sham CCl hrs Figure S. Decreased CCL expression in IRF-deficient macrophages.. heatmap from transcriptomic analysis of chemokine (C-C motif) ligand (CCL) and interferon regulatory factor (IRF) mrn expression in liver F/ + cells from mice with myeloid specific deletion of IRF (MKO) and wild-type littermates (MWT) following experimental fibrosis (wks) by carbon tetrachloride (CCl ) administration. B. IRF mrn expression in liver F/ + cells following experimental fibrosis (wks) and acute toxicity (hrs) by CCl. N= per group. ll values reported as mean ± SEM. *p<, ** p<,1 *** p<,1.
B 1 kb IRF peaks ** *** Genes IRF hrs IRF peaks hrs IRF hrs IRF peaks hrs Fasl 3 3 FasL mrn expression Time of LPS stimulation (hrs) Figure S. IRF directly regulated FasL gene expression.. Representative USCS Genome Browser tracks in the Fas ligand (FasL) locus for interferon regulatory factor (IRF) of unstimulated (hrs) or LPS-stimulated (hrs) bone marrow derived macrophages (BMDM). IRF expression and binding peaks highlighted by green bands. B. FasL and IRF mrn expression in unstimulated (hrs) and LPS-stimulated (hrs and hrs) BMDM from wild-type mice (MWT) and mice with myeloid-deficiency of IRF (MKO). N=3. ll values reported as mean ± SEM. *p<, ** p<,1 *** p<,1.
FasL mrn expression 1 1 Fas mrn expression 3 1 < -33 33- < < -33 33- < Steatosis (%) Steatosis (%) B 1 9 r=.3 p<. 1 9 r=.33 p<. log ST (U/L) log ST (U/L) 1 1 1 3 FasL mrn expression Fas mrn expression log LT (U/L) 1 9 r=.3 p<. log LT (U/L) 1 9 r=.39 p<. 3 3 1 1 1 3 FasL mrn expression Fas mrn expression log Bilirubin (mg/dl) 3 r=. p<. log Bilirubin (mg/dl) 3 r=.1 p<.1 1 1 1 3 FasL mrn expression Fas mrn expression 1 r=-. p<.1 1 r=-.3 p<. Prothrombin time (%) 1 Prothrombin time (%) 1 1 1 1 3 FasL mrn expression Fas mrn expression
Figure S. Fas and FasL expression are independent of steatosis in human liver but correlate to markers of liver damage.. Fas ligand (FasL) and Fas mrn expression in liver biopsies from control patients with normal liver (n=), patients with fatty liver (n=1), non-alcoholic steatohepatitis (NSH; n=) and with viral hepatitis C (HCV; n=11) stratified by steatosis grade. B. Correlative analyses between Fas and FasL mrn expression with plasma aspartate and alanine transaminase (ST and LT, respectively) levels, bilirubin levels and prothrombin time (PT) from the same cohort of patients (n=3). Differences between patient groups determined by one-way NOV. Correlative analyses were assessed by Spearman s test. ll values reported as mean ± SEM. *p<, ** p<,1 *** p<,1.
Table S1. Significantly enriched KEGG terms amongst up-regulated transcripts in IRF MKO mice versus MWT mice following experimental fibrosis by CCl KEGG TERM p-value Glycine, serine and threonine metabolism 3,x1-1 Tryptophan metabolism,x1 - Metabolism of xenobiotics by cytochrome P,1x1 - Fatty acid metabolism,1x1 - PPR signaling pathway 1,x1 - KEGG: Kyoto encyclopedia of genes and genomes; MKO: myeloid-specific knockout; MWT: wild-type; CCl : carbon tetrachloride. Table S. Significantly enriched GO terms amongst up-regulated transcripts in IRF MKO mice versus MWT mice following experimental fibrosis by CCl GO TERM p-value Carboxylic acid metabolic process,x1-3 Oxoacid metabolic process,x1-3 Fatty acid metabolic process 1,x1-11 Lipid metabolic process,x1-11 Gluconeogenesis 1,x1 - GO: gene ontology; MKO: myeloid-specific knockout; MWT: wild-type; CCl : carbon tetrachloride. 9
Table S3. Primers applied for PCR genotyping of MWT and MKO mice Primer IRF flox forward IRF flox reverse LyzM cre mutant LyzM cre wild-type LyzM cre common Sequence '-3' CGT GT GC CTC CT GCT CT GG GCC TGT CC G TT GG CCC G T GCC G TT CG TT CG TCG GCC GG CTG C CTT GGG CTG CC G TTT CTC 1
Table S. Primers applied for qrt-pcr analysis of gene expression in human and murine samples with use of SYBR green chemistry. Gene Forward sequence '-3' Reverse sequence '-3' IRF (mouse) GTGGGGCCCCTCTT GGCTTTTGTTGGGCCG F/ (mouse) CTCTGTGGCTGCCTCCCT CCTTGGGGCCTTCTGGTC Col1α1 (mouse) CCCCCGCGGCTCT GCCCCTTGTGTCTCTCCTC IRF (human) TTTTCTGCTCCCCTGGG GCTCTTGTTGGGCCGC GPDH (human) TCCCTCCCTCTTCC TGGCTCCCGCGTCTC 1S (human) TTCGCGTCTGCCCTTC TGGTGGCCGGCGCT TNF (human) CGCCTCTTCTCCTTCCTG GCCGGGGCTGTTGG IL1β (human) CGTGGTGCTCCTTCC GTCGGGTTCGTGCTGGT αsm (mouse) GGCTCTCCTTCCG CCTTCGCTCTCTCC IL1β (mouse) CCCCGTGTTTCTCCTG GTCCCCTCTCCGCTGC MHCII (mouse) GCTCTCGGGCCTTGCG CGGCCCTCTGGCC IL (mouse) CCCGGCCTTCCCTCTTC TCCCGTTTCCCGGC TNF (mouse) CCCCCGCTCTTCTGTCT CCTTGGTGGTTTGCTCG RG1 (mouse) CTTTGGGTGGTGCTCC TGGTCTCTGGGCTTTCCTTT TGFβ1 (mouse) CCCTGCCCCTTTTTGG TGGTTGTGGGGCGGC IL1 (mouse) GGTTGCCGCCTTTCGG CCTGCTCCCTGCCTTGCT CD (mouse) CCTCTGGTGCGGTGT CTTCCTTTGGTCGCTTTGG FasL (mouse) CTCCCCCTCCCCTG GTTCTGCCGTTCCTTCTGC Fas (mouse) TGTGCTGGCCCTTG TTCGGGTCTCCTGTCTCC BCL (mouse) TGGTCCTGCCGGCTCT GCTCCCGCCTCCGTTT BCL-X L (mouse) GCTGGGCCTTTTGTGGT TGTCTGGTCCTTCCGCTG Fas (human) TCGTCGGGTTGGGGG CGGCCTTCCGTTCTGG FasL (human) GCCTTTGGGTTCTTTCC CCTCCTTTGTCTGGCTCT GPDH (mouse) GTGGCCTCTGGCCTCT TGTGGGGGTGCTCGTG 1S (mouse) GGGGCCTGGCGGC GGGTCGGGGTGGGTTTT 11
Table S. ntibodies applied for immunohistochemical analysis of protein expression in human and murine samples. Epitope Working dilution Company Product number F/ (mouse) 1:1 bcam ab αsm (mouse) 1: bcam ab9 FasL (mouse) 1:1 bcam ab1 IRF (mouse) 1: bcam ab33 IRF (human) 1: Proteintech 1-1-P CD (human) 1: Dako M11 ERG (human) 1: bcam ab913 αsm (human) 1: Dako M1 1
Table S. ntibodies applied for flow cytometric analysis of murine leukocyte populations. Marker Flourochrome Product number Company Working dilution Epitope position Viability mcyan L39 Life Tech 1:1 surface TCRβ Brilliant Violet 11 313 BD 1:1 surface F/ PE-Cy -- ebiosciences 1: surface CD Brilliant Violet 13 BioLegend 1: surface CD PE-eFlour 1 1-1- ebiosciences 1:1 surface CD PerCP-Cy. 99 BD 1:3 surface CD lexa Flour -1- ebiosciences 1: surface CD PC 19 BD 1: surface CD FITC 11 BioLegend 1: surface CD19 Brilliant Violet 111 BioLegend 1:3 surface CD11c PC 1-11-1 ebiosciences 1:1 surface CD11b Brilliant Violet 113 BioLegend 1:3 surface TNF eflour -31- ebiosciences 1: intracellular IL PE 1-1-1 ebiosciences 1:1 intracellular IL1 Brilliant Violet 11 BD 1:1 intracellular IL13 PECy -133- ebiosciences 1:1 intracellular Il1 PC 1-11- ebiosciences 1:1 intracellular IFNγ FITC 11 BD 1:1 intracellular FoxP3 PE 1-3- ebiosciences 1:1 intracellular FSL PerCP-eFlour 1-911- ebiosciences 1:3 intracellular 13